Poland· PL-100497055
ZYNYZ
A retifanlimab product containing retifanlimabum, registered in Poland by Incyte Biosciences Distribution B.V.. The same ATC class is registered in 10 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Retifanlimab is registered in 10 of 19 countries.
Countries holding a registration under ATC L01FF10 (retifanlimab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Retifanlimab · ATC L01FF10
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Retifanlimabum
- Manufacturer
- Incyte Biosciences Distribution B.V.
- Country
- Poland (PL)
- ATC code
- L01FF10
- ATC class
- Retifanlimab
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin04150197693298
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Retifanlimab in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandZYNYZ 500 mg/20 ml, solution à diluer pour perfusionIncyte Biosciences International Sàrl
- United StatesZYNYZIncyte Corporation
- CzechiaZYNYZIncyte Biosciences Distribution B.V., Amsterdam
- SpainZYNYZ 500 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONIncyte Biosciences Distribution B.V.
- FinlandZYNYZIncyte Biosciences Distribution B.V.
- BelgiumZynyz 500 mgIncyte Biosciences Distribution
- IcelandZynyzIncyte Biosciences Distribution B.V.
- Japanレチファンリマブ（遺伝子組換え）インサイト・バイオサイエンシズ・ジャパン
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zynyz
- Liechtenstein · Zynyz
- Norway · Zynyz
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8036c5ee-8b16-44c3-ab92-87e251c2f1a1 GET /v1/drugs/8036c5ee-8b16-44c3-ab92-87e251c2f1a1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "25 mg/ml",
"packaging": "Rpz ¦ EU/1/24/1800/001 ¦ 154393\n1 fiol. 20 ml\n¦ UR/Z/4b/124/26 - 04150197693298",
"substance": "Retifanlimabum 25 mg/ml",
"common_name": "Retifanlimabum",
"pl_product_id": "100497055",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about retifanlimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.